- Black Diamond Therapeutics Presents Promising BDTX-1535 Clinical Data in Patients with Recurrent Glioblastoma at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
- Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference
- Black Diamond Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
- Black Diamond Therapeutics Announces Presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
- Black Diamond Therapeutics Announces Changes to Board of Directors
- Black Diamond Therapeutics Presents Novel Real-World Evidence of the Evolving EGFR Mutation Landscape in NSCLC and the Opportunity for BDTX-1535 in an Oral Presentation at the 2024 American Association of Cancer Research Annual Meeting
- Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
- Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
- Black Diamond Therapeutics Announces Upcoming Presentation at AACR Annual Meeting 2024
- Black Diamond Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
More ▼
Key statistics
On Wednesday, Black Diamond Therapeutics Inc (BDTX:NSQ) closed at 4.44, 174.07% above the 52 week low of 1.62 set on Nov 10, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 4.23 |
---|---|
High | 4.45 |
Low | 4.15 |
Bid | 4.00 |
Offer | 5.00 |
Previous close | 4.21 |
Average volume | 1.16m |
---|---|
Shares outstanding | 56.25m |
Free float | 54.94m |
P/E (TTM) | -- |
Market cap | 249.76m USD |
EPS (TTM) | -1.70 USD |
Data delayed at least 15 minutes, as of Jul 03 2024 18:00 BST.
More ▼